(Reuters) -Eli Lilly’s blockbuster obesity drug Mounjaro became India’s top-selling drug by value for the month of October with sales hitting 1 billion rupees ($11.38 million), research firm Pharmarack said on Friday.

Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world’s most populous nation.

Lilly launched Mounjaro in March, beating rival Novo Nordisk’s Wegovy launch in June, and has since generated a revenue of 3.33 billion rupees till end of October, the firm said.

Mounjaro’s consumption in India by volume was 10 times more than Wegovy in October, the firm said.

(Reporting by Rishika Sadam; Editing by Janane Venkatraman)

See Full Page